MGTA NASDAQ
Magenta Therapeutics, Inc.
1W: -6.0%
1M: -10.9%
3M: -0.1%
1Y: -65.5%
3Y: -90.0%
5Y: -94.7%
$0.70
Last traded 2023-09-11 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Revenue Segmentation
By Product / Service
Revenue by Segment (5-Year Trend)
Income Trends
Revenue
$2M
-67.3% ▼
Gross Profit
$0
+0.0% ▲
Operating Income
-$178M
-74.7% ▼
Net Income
-$162M
-91.1% ▼
EPS (Diluted)
$0.00
+100.0% ▲
EBITDA
-$178M
-74.7% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $6M | $2M |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | -67.3% |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | — | — | — | 0.0% | 0.0% |
| R&D Expenses | $51M | $47M | $55M | $83M | $146M |
| SG&A Expenses | $28M | $28M | $26M | $25M | $34M |
| Operating Expenses | $79M | $75M | $81M | $108M | $180M |
| Operating Income | -$79M | -$75M | -$81M | -$102M | -$178M |
| Operating Margin | — | — | — | -1633.7% | -8739.3% |
| Interest Expense | $0 | $0 | -$4M | $0 | $0 |
| Income Before Tax | -$75M | -$71M | -$76M | -$85M | -$162M |
| Tax Expense | -$6M | -$6M | -$4M | $0 | $0 |
| Net Income | -$69M | -$66M | -$72M | -$85M | -$162M |
| Net Margin | — | — | — | -1362.8% | -7973.3% |
| EPS (Diluted) | $-1.43 | $-1.12 | $-23.05 | $-21.75 | $0.00 |
| EBITDA | -$79M | -$75M | -$79M | -$102M | -$178M |
| Shares Outstanding | 48M | 59M | 3M | 4M | 0 |